Last reviewed · How we verify
NCT07126119
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
Phase 2 trial testing Nab-Paclitaxel in Upper Tract Urothelial Carcinoma in 35 participants. Currently enrolling.
30 December 2026
Quick facts
| Lead sponsor | Tianjin Medical University Second Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 5 July 2025 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- Nab-Paclitaxel (nab-paclitaxel) — full drug profile →
- Tislelizumab (TISLELIZUMAB) — full drug profile →
- Radical nephroureterectomy (RNU)
Conditions studied
- Upper Tract Urothelial Carcinoma — all drugs for Upper Tract Urothelial Carcinoma →
- Neoadjuvant Therapy — all drugs for Neoadjuvant Therapy →
- PD-1 Inhibitor — all drugs for PD-1 Inhibitor →
- Nab-paclitaxel — all drugs for Nab-paclitaxel →
Sponsor
Tianjin Medical University Second Hospital
Who can join
18 and older, any sex, with Upper Tract Urothelial Carcinoma or Neoadjuvant Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed as an open-label, single-arm, single center, phase II clinical trial, aiming to evaluate the efficacy of neoadjuvant Tislelizumab combined with Nab-Paclitaxel for patients with non-metastatic upper tract urothelial carcinoma (UTC). Patients enrolled will receive 2-3 cycles of Tislelizumab in combination with Nab-Paclitaxel every 3 weeks and then undergo radical nephroureterectomy (RNU). The assessment of efficacy is based on the histology of specimen from RNU, and treatment-related adverse events (TRAEs) will be recorded and evaluated according to CTCAE 5.0.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07126119
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nab-Paclitaxel
Trials testing the same drug.
- NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
- NCT06439693 — The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · Phase 2 · recruiting
- NCT06472037 — AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC · Phase 2 · recruiting
- NCT06059001 — Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC · Phase 1 · active not recruiting
- NCT05852691 — A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Unt · Phase 2 · active not recruiting
Other recruiting trials for Upper Tract Urothelial Carcinoma
Currently open trials in the same condition.
- NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
- NCT07321210 — Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma · NA · recruiting
- NCT07225374 — Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC · Phase 2 · recruiting
- NCT06848868 — Ambulatory Flexible URS for UTUC Surveillance · Phase 1 · recruiting
- NCT06040762 — A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and U · NA · recruiting
Other Tianjin Medical University Second Hospital trials
Trials by the same sponsor.
- NCT07170293 — Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07321197 — Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC): A Rand · NA · not yet recruiting
- NCT07321210 — Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma · NA · recruiting
- NCT07233252 — Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07126119 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Second Hospital
- Last refreshed: 17 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07126119.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing